Local Innovator Fights Cancer with Ground-Breaking Biotechnology
Keystone Nano, with Help from Ben Franklin Technology Partners, Sets Sights on Liver Cancer
Keystone Nano is targeting a killer that claims approximately 700,000 lives each year, with no effective treatment—liver cancer. With the company’s recently unveiled Ceramide NanoLiposome (CNL), they expect to be able to effectively kill cancer cells, while leaving normal cells unharmed, a process nearly unheard of in the world of cancer therapies. This means great things for cancer patients, including reduced negative side effects that result from most traditional cancer treatments, as well as a greater likelihood of treatment success.
Read more: Local Innovator Fights Cancer with Ground-Breaking Biotechnology